Ocular Therapeutix™ Reports Third Quarter 2016 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Ocular Therapeutix (OCUL) Tops Q3 EPS by 11c
November 9, 2016 7:01 AM ESTOcular Therapeutix (NASDAQ: OCUL) reported Q3 EPS of ($0.39), $0.11 better than the analyst estimate of ($0.50). Revenue for the quarter came in at $477 thousand versus the consensus estimate of $470 thousand.
For earnings history and earnings-related data on Ocular Therapeutix (OCUL) click here.
... More